An agent that blocks the release of adrenergic transmitters and may have other actions. It was formerly used as an antihypertensive agent, but is now proposed as an anti-arrhythmic.
The TEMPERATURE at the outer surface of the body.
An indole-dione that is obtained by oxidation of indigo blue. It is a MONOAMINE OXIDASE INHIBITOR and high levels have been found in urine of PARKINSONISM patients.
The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.
An antidepressive agent that has also been used in the treatment of movement disorders. The mechanism of action is not well understood.
Unstable isotopes of fluorine that decay or disintegrate emitting radiation. F atoms with atomic weights 17, 18, and 20-22 are radioactive fluorine isotopes.
A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.
A broad category of chemical actions and uses that result in the prevention, treatment, cure or diagnosis of disease. Included here are drugs and chemicals that act by altering normal body functions, such as the REPRODUCTIVE CONTROL AGENTS and ANESTHETICS. Effects of chemicals on the environment are also included.
A synthetic pregnadiene compound with anti-aldosterone activity.
The period of time following the triggering of an ACTION POTENTIAL when the CELL MEMBRANE has changed to an unexcitable state and is gradually restored to the resting (excitable) state. During the absolute refractory period no other stimulus can trigger a response. This is followed by the relative refractory period during which the cell gradually becomes more excitable and the stronger impulse that is required to illicit a response gradually lessens to that required during the resting state.
Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
Drugs that inhibit the actions of the sympathetic nervous system by any mechanism. The most common of these are the ADRENERGIC ANTAGONISTS and drugs that deplete norepinephrine or reduce the release of transmitters from adrenergic postganglionic terminals (see ADRENERGIC AGENTS). Drugs that act in the central nervous system to reduce sympathetic activity (e.g., centrally acting alpha-2 adrenergic agonists, see ADRENERGIC ALPHA-AGONISTS) are included here.
Exclusive legal rights or privileges applied to inventions, plants, etc.
Precursor of epinephrine that is secreted by the adrenal medulla and is a widespread central and autonomic neurotransmitter. Norepinephrine is the principal transmitter of most postganglionic sympathetic fibers and of the diffuse projection system in the brain arising from the locus ceruleus. It is also found in plants and is used pharmacologically as a sympathomimetic.
An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
Drugs that selectively bind to and activate alpha adrenergic receptors.
Compounds that bind to and activate ADRENERGIC ALPHA-2 RECEPTORS.
Works containing information articles on subjects in every field of knowledge, usually arranged in alphabetical order, or a similar work limited to a special field or subject. (From The ALA Glossary of Library and Information Science, 1983)
Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients.
A voluntary organization concerned with the prevention and treatment of heart and vascular diseases.
The thoracolumbar division of the autonomic nervous system. Sympathetic preganglionic fibers originate in neurons of the intermediolateral column of the spinal cord and project to the paravertebral and prevertebral ganglia, which in turn project to target organs. The sympathetic nervous system mediates the body's response to stressful situations, i.e., the fight or flight reactions. It often acts reciprocally to the parasympathetic system.
A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
The geometric and structural changes that the HEART VENTRICLES undergo, usually following MYOCARDIAL INFARCTION. It comprises expansion of the infarct and dilatation of the healthy ventricle segments. While most prevalent in the left ventricle, it can also occur in the right ventricle.
Cardiac electrical stimulators that apply brief high-voltage electroshocks to the HEART. These stimulators are used to restore normal rhythm and contractile function in hearts of patients who are experiencing VENTRICULAR FIBRILLATION or ventricular tachycardia (TACHYCARDIA, VENTRICULAR) that is not accompanied by a palpable PULSE. Some defibrillators may also be used to correct certain noncritical dysrhythmias (called synchronized defibrillation or CARDIOVERSION), using relatively low-level discharges synchronized to the patient's ECG waveform. (UMDNS, 2003)
Recording of the moment-to-moment electromotive forces of the HEART as projected onto various sites on the body's surface, delineated as a scalar function of time. The recording is monitored by a tracing on slow moving chart paper or by observing it on a cardioscope, which is a CATHODE RAY TUBE DISPLAY.
The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow.
The field of veterinary medicine concerned with the causes of and changes produced in the body by disease.
A monoamine oxidase inhibitor with antihypertensive properties.
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
An acute inflammatory autoimmune neuritis caused by T cell- mediated cellular immune response directed towards peripheral myelin. Demyelination occurs in peripheral nerves and nerve roots. The process is often preceded by a viral or bacterial infection, surgery, immunization, lymphoma, or exposure to toxins. Common clinical manifestations include progressive weakness, loss of sensation, and loss of deep tendon reflexes. Weakness of respiratory muscles and autonomic dysfunction may occur. (From Adams et al., Principles of Neurology, 6th ed, pp1312-1314)
A slowly progressive autoimmune demyelinating disease of peripheral nerves and nerve roots. Clinical manifestations include weakness and sensory loss in the extremities and enlargement of peripheral nerves. The course may be relapsing-remitting or demonstrate a step-wise progression. Protein is usually elevated in the spinal fluid and cranial nerves are typically spared. GUILLAIN-BARRE SYNDROME features a relatively rapid progression of disease which distinguishes it from this condition. (Adams et al., Principles of Neurology, 6th ed, p1337)
A form of necrotizing non-granulomatous inflammation occurring primarily in medium-sized ARTERIES, often with microaneurysms. It is characterized by muscle, joint, and abdominal pain resulting from arterial infarction and scarring in affected organs. Polyarteritis nodosa with lung involvement is called CHURG-STRAUSS SYNDROME.
Progressive myopathies characterized by the presence of inclusion bodies on muscle biopsy. Sporadic and hereditary forms have been described. The sporadic form is an acquired, adult-onset inflammatory vacuolar myopathy affecting proximal and distal muscles. Familial forms usually begin in childhood and lack inflammatory changes. Both forms feature intracytoplasmic and intranuclear inclusions in muscle tissue. (Adams et al., Principles of Neurology, 6th ed, pp1409-10)
Diseases characterized by injury or dysfunction involving multiple peripheral nerves and nerve roots. The process may primarily affect myelin or nerve axons. Two of the more common demyelinating forms are acute inflammatory polyradiculopathy (GUILLAIN-BARRE SYNDROME) and POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING. Polyradiculoneuritis refers to inflammation of multiple peripheral nerves and spinal nerve roots.
Inflammation of a muscle or muscle tissue.
A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459)
Substances made up of an aggregation of small particles, as that obtained by grinding or trituration of a solid drug. In pharmacy it is a form in which substances are administered. (From Dorland, 28th ed)
Legally authorized corporations owned and managed by one or more professionals (medical, dental, legal) in which the income is ascribed primarily to the professional activities of the owners or stockholders.
A device that delivers medication to the lungs in the form of a dry powder.
Method of using a polycrystalline powder and Rietveld refinement (LEAST SQUARES ANALYSIS) of X-RAY DIFFRACTION or NEUTRON DIFFRACTION. It circumvents the difficulties of producing single large crystals.
Relating to the size of solids.
The secretion of histamine from mast cell and basophil granules by exocytosis. This can be initiated by a number of factors, all of which involve binding of IgE, cross-linked by antigen, to the mast cell or basophil's Fc receptors. Once released, histamine binds to a number of different target cell receptors and exerts a wide variety of effects.

Aerobic training and cutaneous vasodilation in young and older men. (1/30)

To determine the effect and underlying mechanisms of exercise training and the influence of age on the skin blood flow (SkBF) response to exercise in a hot environment, 22 young (Y; 18-30 yr) and 21 older (O; 61-78 yr) men were assigned to 16 wk of aerobic (A; YA, n = 8; OA, n = 11), resistance (R; YR, n = 7; OR, n = 3), or no training (C; YC, n = 7; OC, n = 7). Before and after treatment, subjects exercised at 60% of maximum oxygen consumption (VO2 max) on a cycle ergometer for 60 min at 36 degrees C. Cutaneous vascular conductance, defined as SkBF divided by mean arterial pressure, was monitored at control (vasoconstriction intact) and bretylium-treated (vasoconstriction blocked) sites on the forearm using laser-Doppler flowmetry. Forearm vascular conductance was calculated as forearm blood flow (venous occlusion plethysmography) divided by mean arterial pressure. Esophageal and skin temperatures were recorded. Only aerobic training (functionally defined a priori as a 5% or greater increase in VO2 max) produced a decrease in the mean body temperature threshold for increasing forearm vascular conductance (36.89 +/- 0.08 to 36.63 +/- 0.08 degrees C, P < 0.003) and cutaneous vascular conductance (36.91 +/- 0.08 to 36.65 +/- 0.08 degrees C, P < 0.004). Similar thresholds between control and bretylium-treated sites indicated that the decrease was mediated through the active vasodilator system. This shift was more pronounced in the older men who presented greater training-induced increases in VO2 max than did the young men (22 and 9%, respectively). In summary, older men improved their SkBF response to exercise-heat stress through the effect of aerobic training on the cutaneous vasodilator system.  (+info)

Baroreceptor modulation of active cutaneous vasodilation during dynamic exercise in humans. (2/30)

The hypothesis that baroreceptor unloading during dynamic limits cutaneous vasodilation by withdrawal of active vasodilator activity was tested in seven human subjects. Increases in forearm skin blood flow (laser-Doppler velocimetry) at skin sites with (control) and without alpha-adrenergic vasoconstrictor activity (vasodilator only) and in arterial blood pressure (noninvasive) were measured and used to calculate cutaneous vascular conductance (CVC). Subjects performed two similar dynamic exercise (119 +/- 8 W) protocols with and without baroreceptor unloading induced by application of -40 mmHg lower body negative pressure (LBNP). The LBNP condition was reversed (i.e., either removed or applied) after 15 min while exercise continued for an additional 15 min. During exercise without LBNP, the increase in body core temperature (esophageal temperature) required to elicit active cutaneous vasodilation averaged 0.25 +/- 0.08 and 0.31 +/- 0.10 degrees C (SE) at control and vasodilator-only skin sites, respectively, and increased to 0.44 +/- 0.10 and 0.50 +/- 0.10 degrees C (P < 0.05 compared with without LBNP) during exercise with LBNP. During exercise baroreceptor unloading delayed the onset of cutaneous vasodilation and limited peak CVC at vasodilator-only skin sites. These data support the hypothesis that during exercise baroreceptor unloading modulates active cutaneous vasodilation.  (+info)

Gradation of the reflex response from atrial receptors. (3/30)

1. In anaesthetized dogs, distension of balloons so as to stimulate atrial receptors resulted in a reflex increase in heart rate. 2. Successive distensions of one, two and three balloons positioned in the left upper and middle pulmonary vein-atrial junctions and in the left atrial appendage resulted in a progressive increase in the magnitude of this response. 3. It is concluded that the magnitude of the increase in heart rate is related to the extent of receptor area stimulated.  (+info)

Neurogenic sympathetic vasoconstriction of the rabbit basilar artery. (4/30)

When examined by fluorescence microscopy the rabbit basilar artery contains a rich adrenergic-like plexus at the adventitiomedial junction. The fluorescence disappears upon chronic reserpinization and bilateral superior cervical ganglionectomy. Transmural stimulation of intramural nerves a results in a response which is predominantly constrictor but also contains a small, inconstant dilator component. The constrictor response is abolished by chronic reserpinization, bilateral superior cervical ganglionectomy, and cold storage of the preparation. The constriction is prevented by the adrenergic neuron blocking agents guanethidine and bretylium but not by such alpha-adrenergic receptor blocking agents as phenoxybenzamine (PBZ), phentolamine, and tolazoline. Our results show that doses of the three latter agents sufficient to abolish contractions to norepinephrine (NE) in concentrations of up to 10(-2) M only potentiate and prolong the contractile response to nerve stimulation. The beta-adrenergic receptor blocking agent, propranolol, and inhibitors of NE neuronal uptake, such as desipramine (desmethylimipramine, DMI) and cocaine, do not influence the size of the neurogenic response. These results suggest that the vasoconstrictor component of the rabbit basilar artery response to transmural nerve stimulation (TNS) is mediated via sympathetic adrenergic-like neurons, but at the same time also raise the question whether the transmission process is typical of classic adrenergic neuroeffector mechanisms.  (+info)

Cutaneous active vasodilation in humans during passive heating postexercise. (5/30)

The hypothesis that exercise causes an increase in the postexercise esophageal temperature threshold for onset of cutaneous vasodilation through an alteration of active vasodilator activity was tested in nine subjects. Increases in forearm skin blood flow and arterial blood pressure were measured and used to calculate cutaneous vascular conductance at two superficial forearm sites: one with intact alpha-adrenergic vasoconstrictor activity (untreated) and one infused with bretylium tosylate (bretylium treated). Subjects remained seated resting for 15 min (no-exercise) or performed 15 min of treadmill running at either 55, 70, or 85% of peak oxygen consumption followed by 20 min of seated recovery. A liquid-conditioned suit was used to increase mean skin temperature ( approximately 4.0 degrees C/h), while local forearm temperature was clamped at 34 degrees C, until cutaneous vasodilation. No differences in the postexercise threshold for cutaneous vasodilation between untreated and bretylium-treated sites were observed for either the no-exercise or exercise trials. Exercise resulted in an increase in the postexercise threshold for cutaneous vasodilation of 0.19 +/- 0.01, 0.39 +/- 0.02, and 0.53 +/- 0.02 degrees C above those of the no-exercise resting values for the untreated site (P < 0.05). Similarly, there was an increase of 0.20 +/- 0.01, 0.37 +/- 0.02, and 0.53 +/- 0.02 degrees C for the treated site for the 55, 70, and 85% exercise trials, respectively (P < 0.05). It is concluded that reflex activity associated with the postexercise increase in the onset threshold for cutaneous vasodilation is more likely mediated through an alteration of active vasodilator activity rather than through adrenergic vasoconstrictor activity.  (+info)

The effects of ventricular end-diastolic and systolic pressures on action potential and duration in anaesthetized dogs. (6/30)

1. Although it is known that mechanical events in the heart influence the duration of the cardiac action potential, there is no quantitative information on the effects of independent changes in ventricular end-diastolic and systolic pressures. 2. Experiments were carried out on open-chest anaesthetized dogs in which the autonomic nervous influences on the heart were prevented and monophasic action potentials were recorded form the epicardial surface of the left ventricle. The duration of these action potentials was taken as the interval from the upstroke to the point of 90% repolarization. 3. Elevation of left ventricular peak systolic pressure, at constant end-diastolic pressure, significantly shortened the monophasic action potential. 4. Elevation of end-diastolic pressure at constant peak systolic pressure significantly lengthened the monophasic action potential. 5. Responses were not dependent on release of noradrenaline from sympathetic nerve terminals because they persisted after administration of bretylium tosylate. They were also not due to myocardial ischaemia because they persisted when coronary perfusion pressure was maintained at a constant high level. 6. Simultaneous recordings of changes in myocardial segment length showed the expected responses to changes in ventricular pressures: increases in shortening in response to increases in diastolic pressure and no consistent effect from changes in systolic pressure. 7. These investigations demonstrate the independent effects of changes in systolic and end-diastolic pressures on cardiac action potential duration. This effect is likely to be an effect of the mechanical events, i.e. contraction-excitation feedback. This response may be mediated through changes in myocardial fibre tension, the consequent changes in fibre shortening, or both.  (+info)

Sympathetic, sensory, and nonneuronal contributions to the cutaneous vasoconstrictor response to local cooling. (7/30)

Previous work indicates that sympathetic nerves participate in the vascular responses to direct cooling of the skin in humans. We evaluated this hypothesis further in a four-part series by measuring changes in cutaneous vascular conductance (CVC) from forearm skin locally cooled from 34 to 29 degrees C for 30 min. In part 1, bretylium tosylate reversed the initial vasoconstriction (-14 +/- 6.6% control CVC, first 5 min) to one of vasodilation (+19.7 +/- 7.7%) but did not affect the response at 30 min (-30.6 +/- 9% control, -38.9 +/- 6.9% bretylium; both P < 0.05, P > 0.05 between treatments). In part 2, yohimbine and propranolol (YP) also reversed the initial vasoconstriction (-14.3 +/- 4.2% control) to vasodilation (+26.3 +/- 12.1% YP), without a significant effect on the 30-min response (-26.7 +/- 6.1% YP, -43.2 +/- 6.5% control; both P < 0.05, P > 0.05 between sites). In part 3, the NPY Y1 receptor antagonist BIBP 3226 had no significant effect on either phase of vasoconstriction (P > 0.05 between sites both times). In part 4, sensory nerve blockade by anesthetic cream (Emla) also reversed the initial vasoconstriction (-20.1 +/- 6.4% control) to one of vasodilation (+213.4 +/- 87.0% Emla), whereas the final levels did not differ significantly (-37.7 +/- 10.1% control, -37.2 +/- 8.7% Emla; both P < 0.05, P > 0.05 between treatments). These results indicate that local cooling causes cold-sensitive afferents to activate sympathetic nerves to release norepinephrine, leading to a local cutaneous vasoconstriction that masks a nonneurogenic vasodilation. Later, a vasoconstriction develops with or without functional sensory or sympathetic nerves.  (+info)

Delayed threshold for active cutaneous vasodilation in patients with Type 2 diabetes mellitus. (8/30)

Epidemiological evidence suggests decreased heat tolerance in patients with Type 2 diabetes mellitus (T2DM), but it is not known whether the mechanisms involved in thermoregulatory control of skin blood flow are altered in these patients. We tested the hypothesis that individuals with T2DM have a delayed internal temperature threshold for active cutaneous vasodilation during whole body heating compared with healthy control subjects. We measured skin blood flow using laser-Doppler flowmetry (LDF), internal temperature (T or) via sublingual thermocouple, and mean arterial pressure via Finometer at baseline and during whole body heating in 9 T2DM patients and 10 control subjects of similar age, height, and weight. At one LDF site, sympathetic noradrenergic neurotransmission was blocked by local pretreatment with bretylium tosylate (BT) to isolate the cutaneous active vasodilator system. Whole body heating was conducted using a water-perfused suit. There were no differences in preheating T(or) between groups (P > 0.10). Patients with T2DM exhibited an increased internal temperature threshold for the onset of vasodilation at both untreated and BT-treated sites. At BT-treated sites, T or thresholds were 36.28 +/- 0.07 degrees C in controls and 36.55 +/- 0.05 degrees C in T2DM patients (P < 0.05), indicating delayed onset of active vasodilation in patients. Sensitivity of vasodilation was variable in both groups, with no consistent difference between groups (P > 0.05). We conclude that altered control of active cutaneous vasodilation may contribute to impaired thermoregulation in patients with T2DM.  (+info)

In case of contact with eyes, flush with copious amounts of water for at least 15 minutes. Assure adequate flushing by separating the eyelids with fingers. Call a physician ...
This phase I trial studies the side effects and best dose of Chinese herbal formulation PHY906 when given together with sorafenib tosylate in treating patients with advanced liver cancer. Biological therapies, such as Chinese herbal formulation PHY906, may interfere with the growth of tumor cells and slow the growth of tumors. Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosylate may also stop the growth of liver cancer by blocking blood flow to the tumor. Giving Chinese herbal formulation PHY906 together with sorafenib tosylate may work better in treating advanced liver cancer ...
Edoxaban tosylate (DU-176b) is a selective, potent and orally active factor Xa (FXa) inhibitor with Kis of 0.561 nM and 2.98 nM for free FXa and prothrombinase, respectively. Edoxaban tosylate is an anticoagulant agent and can be used for stroke prevention. Edoxaban tosylate is a also weak inhibitor of thrombin and factor IXaβ (FIXa), with Kis of 6.00 μM and 41.7 μM, respectively, exhibits >10 000-fold selectivity for FXa. Edoxaban tosylate has antithrombotic properties and has potential for thromboembolic diseases treatment. - Mechanism of Action & Protocol.
Bretylium tosylate (Bretylol) has recently been approved for parenteral use against resistant ventricular arrhythmias. The pharmacologic action of bretylium is complex, and its antiarrhythmic action differs significantly from other drugs. Bretylium is an adrenergic neuronal blocking agent taken up selectively at peripheral adrenergic nerve terminals, where it initially releases norepinephrine (sympathomimetic effect) and then produces adrenergic neuronal blockade. It has direct cardiac membrane effect to prolong action potential duration and effective refractory period but, unlike other membrane active antiarrhythmic agents, does not depress conduction velocity or automaticity. Bretylium increases ventricular fibrillation threshold and prevents the decrease in ventricular fibrillation threshold associated with myocardial ischemia. It does not depress myocardial contractility. Clinical studies have shown parenteral bretylium to be effective in suppressing ventricular arrhythmias, particularly ...
RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether sorafenib tosylate is more effective when given with or without gemcitabine hydrochloride and oxaliplatin in treating patients with liver cancer.. PURPOSE: This randomized phase II trial is studying sorafenib tosylate to see how well it works when given with or without gemcitabine hydrochloride and oxaliplatin in treating patients with locally advanced, unresectable, or metastatic liver cancer. ...
WAGHESHWARI IMPEX PRIVATE LIMITED - Manufacturer, Exporter, Service Provider And Trader Of Sorafenib Tosylate,Mumbai,Maharashtra,India. Find More Detail For Sorafenib Tosylate Manufacturers,Exporter,Service Provider And Trader From Mumbai,Maharashtra,India
Drugs. The following drugs were used: bretylium tosylate (Burroughs Wellcome, Research Triangle Park, NC); (-)-cocaine hydrochloride (Merck, Darmstadt, Germany), desipramine hydrochloride (Ciba-Geigy AG, Basel, Switzerland); 1-(3,4-dihydroxyphenyl)-2-methyl-1-propanone (U-0521; The Upjohn Company, Kalamazoo, MI); (-)-norepinephrine hydrochloride (Sigma-Aldrich, St. Louis, MO); (-)-[7-3H] (N)norepinephrine hydrochloride (specific activity, 12.0-14.9 Ci/mmol; PerkinElmer Life Sciences, Boston, MA); pargyline hydrochloride (Abbott Laboratories, North Chicago, IL); and reboxetine hydrochloride, a racemic mixture of (-)-R,R-and (+)-S,S-(2-[α[2-ethoxyphenoxy]benzyl]-morpholine hydrochloride (synthesized in the Department of Medicinal Chemistry, H. Lundbeck A/S, Copenhagen, Denmark).. Stock solutions were prepared in twice-distilled water (bretylium, cocaine, desipramine, norepinephrine, [3H]norepinephrine, and pargyline). The stock solutions were diluted with physiological salt solution (PSS) to the ...
COA of Sorafenib Tosylate contains the actual results obtained from testing performed as part of quality control. View our Sorafenib Tosylate specific physical and chemical properties, and analytical data.
To 15.2 g vanillin (0.1 mol) a calculated amount of kalihydrat (probably KOH) was added and dissolved in 75 ml MeOH. 18 g methyl tosylate (0.1 mol) and heated on a water bath for 1.5 h to reflux. As soon as the the light yellow, clear solution starts boiling the potassium salt of methyl toluenesulfonic acid starts to precipitate. After 1.5 h everything is poured in about 300 ml of H2O. First there is a white emulsion which starts to separate a light yellow oil. The aqeuous solution and the oil is extracted exhaustive with Et2O, the organic phase is washed twice with 10 ml 5% aqeuous KOH to remove unreacted vanillin. The organic phase turns almost colourless, the alkaline solution is light yellow. The organic phase is washed with H2O, dried with freshly sulphate (probably MgSO4 or Na2SO4) and evaporated. The oily residue solidifies on cooling (melting point: 42-43°C ...
RATIONALE: Sorafenib tosylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib tosyla
Product Description Model NO.: hangzhou royall Customized: Non-Customized Suitable for: Elderly, Children, Adult Purity: |99% CAS: 475207-59-1 Grade Standard: Medicine Grade Shelf Life: 2years Standard: USP Ep Jp etc Appearance: White Powder Transport Package: by Sea, by Air, by Express Origin: Zhejiang, China Powder: Yes Certification: GMP, HSE, ISO 9001, USP, BP State: Solid Product Name: Sorafenib Tosylate Type: Antineoplastic Agents Assay: HPLC 99% Application: Pharma Intermediate Package: 1/5/10/20/25 Kg/Drum/CTN/Bag Trademark: royall Specification: 99%min HS Code: 42356122…
Creative Peptides offers D-Alanine benzyl ester tosylate for your research. We also provide custom peptide synthesis, process development, GMP manufacturing.
LY 2584702 tosylate | S6K1 inhibitor | LY 2779964 | LY2584702 | LY2779964 | CAS [1082949-68-5] - [1082949-67-4] | Axon 2464 | Axon Ligand™ with >98% purity available from supplier Axon Medchem, prime source of life science reagents for your research
A look at the following clinical trial: Sorafenib Tosylate With or Without Pravastatin in Treating Patients With Liver Cancer and Cirrhosis
Creative Peptides offers Glycine benzyl ester tosylate for your research. We also provide custom peptide synthesis, process development, GMP manufacturing.
It is unknown whether and to what extent changes in various endothelial functions and adrenergic responsiveness are related to the development of microvascular complications in type 1 diabetes. Therefore, endothelium-dependent and endothelium-independent vasodilatation, endothelium-dependent hemostatic factors, and one and two adrenergic vasoconstrictor responses were determined in type 1 patients with and without microvascular complications. A total of 34 patients with type 1 diabetes were studied under euglycemic conditions on two occasions (11 without microangiopathy, 10 with proliferative and preproliferative retinopathy previously treated by laser coagulation, 13 with microalbuminuria, and 12 healthy volunteers also were studied). Forearm vascular responses to brachial artery infusions of N(G)-monomethyl-L-arginine (L-NMMA), sodium nitroprusside, acetylcholine (ACh), clonidine, and phenylephrine were determined. The ACh infusions were repeated during coinfusion of L-arginine. Furthermore, ...
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identif
In the past two decades, normal endothelial function has been identified as integral to vascular health. The endothelium produces numerous vasodilator and vasoconstrictor compounds that regulate vascular tone; the vasodilator, nitric oxide (NO), has additional antiatherogenic properties, is probably …
In the past two decades, normal endothelial function has been identified as integral to vascular health. The endothelium produces numerous vasodilator and vasoconstrictor compounds that regulate vascu
We are a manufactory for Edoxaban API and its pharmaceutical intermediate. More product infomation, pls contact us: info(at)ansionpharma.com; www.ansionpharma.com Our Products: Chemical Name Edoxaban (tosylate Monohydrate)...
We are a manufactory for Edoxaban API and its pharmaceutical intermediate. More product infomation, pls contact us: info (at)ansionpharma.com; www.ansionpharma.com Our Products: Chemical Name Edoxaban (tosylate Monohydrate)...
Gefitinib 184475-35-2 White or off white crystalline powder ≥99% Sorafenib tosylate 475207-59-1 - Erlotinib Hcl 183319-69-9|Dasatinib monohydrate 863127-77-9 Details.
Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5-10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy. Originally introduced in 1959 for the treatment of hypertension. Its use as an antiarrhythmic for ventricular fibrillation was discovered and patented by Marvin Bacaner in 1969 at the University of Minnesota. The American Heart Association removed bretylium from their 2000 ECC/ACC guidelines due to its unproven efficacy and ongoing supply problems. Many have cited these supply problems as an issue of raw materials needed in the production of Bretylium. By the release of the AHA 2005 ECC/ACC guidelines there is no mention of Bretylium and it is virtually unavailable throughout most of the world. As ...
3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo(4,5-d)pyridazin-4-one tosylate: Dipeptidyl peptidase IV inhibitor; structure in first source
Valbenazine, also known as NBI-98854 and MT-5199, is a potent and selective VMAT2 inhibitor. NBI-98854 is effective in regulating the levels of dopamine release during nerve communication, while at the same time having minimal impact on the other monoamines. NBI-98854 is promising agent for the treatment of tardive dyskinesia.NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. These results support the phase 3 clinical trials of NBI-98854 now underway.
Find information on Bretylium (Bretylol) in Daviss Drug Guide including dosage, side effects, interactions, nursing implications, mechanism of action, half life, administration, and more. Davis Drug Guide PDF.
This phase I trial studies the side effects and best dose of sorafenib tosylate and vorinostat when given together with gemcitabine hydrochloride, paclitaxel
From BioPortfolio: -- Planned submission of NDA for glycopyrronium tosylate (formerly DRM04) in 2H17 on schedule after pre-NDA meeting with FDA ---- Management to host webcast and...
The present invention relates to 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone tosylate salt in crystalline and in solid forms, the method of making and using such crystals.
Atlantic cod (Gadus morhua L.), acclimated to 5 °C, were equipped with ultrasonic transmitters which allowed the continuous monitoring of their vertical movements and heart rate. Fish were then placed in a 125 m3 tower tank in which the various thermal conditions they encounter in their natural environment were reproduced. Physiological and behavioural responses of cod were followed in parallel to the induced environmental changes. The experimental conditions studied in the tower tank were also reproduced in a swimming respirometer, where oxygen consumption and heart rate could be monitored within the activity range of a free-swimming animal. In a homogeneous water column, a rise in temperature induced marked increases in fish swimming activity, heart rate and heart beat-to-beat variability. In a thermally stratified environment, voluntary activity also increased when the thermal structure of the water column was altered, though no temperature-dependent changes in heart rate were observed. ...
A net energy gain (NEG) model was used to assess the effects of turbulence on the energy budget of Atlantic cod Gadus morhua larvae, feeding on copepod nauplii at different concentrations. The geometry of their prey search space was parameterised as either a sphere, hemisphere (the most commonly applied in analogous studies), or wedge. Observed distributions in behaviour (e.g. move duration, pause duration, turn angles) were used as model input, and 2 facets of this behaviour (move duration and move speed) were varied to examine how parameterised changes in foraging behaviour can affect the NEG of the predator. At a prey concentration of 100 l-1, and in static water, NEG is an order of magnitude higher for a hemispherical shape relative to a wedge-shaped search volume. This difference decreases with increasing prey concentration (600 l-1), but always remains considerable. When parameterised turbulence was added, prey capture rates for a larva with a hemispherical search space increases 3 times ...
Identification and characterisation of thirteen new microsatellites for Atlantic cod (Gadus morhua L.) from a repeat-enriched ...
Thompson, Caitlin S., Lacy A. Holowatz, and W. Larry Kenney. Cutaneous vasoconstrictor responses to norepinephrine are attenuated in older humans. Am J Physiol Regul Integr Comp Physiol 288: R1108 -R1113, 2005. First published January 20, 2005; doi:10.1152/ajpregu.00839.2004.-Cutaneous vasoconstriction (VC) in response to cooling is impaired with human aging. On the basis of previous findings that older humans rely predominantly on norepinephrine (NE) for reflex VC of skin blood vessels, and that the VC effects of NE are blunted with age in many vascular beds, we tested the hypothesis that cutaneous VC responses to exogenous NE are attenuated in aged skin compared with young skin. In 11 young (18-30 yr) and 11 older (62-76 yr) men and women, skin blood flow was monitored at two forearm sites with laser Doppler (LD) flowmetry, while local skin temperature was clamped at 34°C. At one site, five doses of NE (10 10 to 10 2 M) were sequentially infused via intradermal microdialysis while the other site
Laboratory Experiment pubs.acs.org/jchemeduc A Two-Step Synthesis of the Laundry Detergent Perfume Additive β‑Citronellyl Tosylate Cheryl M. Mascarenhas*...
C Newman, D Hackett, H El-Tamimi, A Maseri, G Davies; Acetylcholine Has Dose-Dependent Bimodal Effects on Coronary Blood Flow in Man. Clin Sci (Lond) 1 January 1988; 74 (s18): 45P. doi: https://doi.org/10.1042/cs074045P. Download citation file:. ...
Homogeneous catalytic dehydration of sorbitol to isosorbide has been performed with a series of metal tosylates as catalysts. Conversions up to 100 % and selectivities into isosorbide up to 67% were obtained with Bi(OTs)3. The metals were exchanged with acidic sites of sulfonic resins and the resulting materials were evaluated as heterogeneous catalysts. On the contrary to their homogeneous counter parts, the heterogenized metal sites are non-active. The catalytic activity of the modified resins was systematically diminished in comparison to the native resins. The inhibition is greatly dependent on the nature of the metal and, on a larger extent, of the used resin for the cation exchange.
Foreign chemicals in teleost fish are primarily excreted via urine and bile. Xenobiotics and their metabolites excreted via urine are filtered in the glomerulus and/or secreted by tubular transport within the kidney. Contrary to most fish species, such as the Atlantic cod Gadus morhua, the polar cod Boreogadus saida displays a complete absence of the glomerular apparatus. We examined the excretory routes in an aglomerular (B. saida) vs a glomerular (G. morhua) gadoid fish. Using an inert polysacharride as a model compound, it is demonstrated that this xenobiotic is excreted solely via the urine in G. morhua and via the bile in B. saida. ...
The duodenal epithelium secretes HC03-at higher rates than does the stomach (or more distal small intestine) and the duodenal secretion is currently accepted as the most important defence mechanism...
SiliaBond Tosyl Chloride (Si-TsCl) readily reacts with nucleophiles such as amines and alcohols. Reaction with alcohols yields the bound tosylate, which can then be used to synthesize amines and oxazolines.
When running in vivo experiments, it is imperative to keep arterial blood pressure and acid-base parameters within the normal physiological range. The aim of this investigation was to explore the consequences of anesthesia-induced acidosis on basal and PGE2-stimulated duodenal bicarbonate secretion. Mice (strain C57bl/6J) were kept anesthetized by a spontaneous inhalation of isoflurane. Mean arterial blood pressure (MAP), arterial acid-base balance, and duodenal mucosal bicarbonate secretion (DMBS) were studied. Two intra-arterial fluid support strategies were used: a standard Ringer solution and an isotonic Na2CO3 solution. Duodenal single perfusion was used, and DMBS was assessed by back titration of the effluent. PGE2 was used to stimulate DMBS. In Ringer solution-infused mice, isoflurane-induced acidosis became worse with time. The blood pH was 7.15-7.21 and the base excess was about -8 mM at the end of experiments. The continuous infusion of Na2CO3 solution completely compensated for the ...
Allergan Plc, TheraVida Inc., and GlaxoSmithKline Plc have one drug candidate each in the Phase II development for the treatment of hyperhidrosis. Glycopyrronium tosylate is the only drug candidate that has the Phase III stage of development for the treatment of hyperhidrosis. Majority of the pipeline drug candidates are being developed using the topical route of administration.. Download Report Sample at: https://www.psmarketresearch.com/market-analysis/hyperhidrosis-therapeutics-pipeline-analysis/report-sample. Major players in the market are putting more emphasis on targeting cholinergic receptors. The drug candidates used for the treatment of hyperhidrosis, act on cholinergic receptors and block its activity that interfere with sweating. For instance, Glycopyrronium tosylate, a Phase III drug candidate by Dermira, Inc. acts topically and blocks the cholinergic receptor.. Make Enquiry Before Buying the Report: ...
ABSTRACT: The performance of aquaculture escapees in the wild depends in part on how their morphology differs from that of wild fish. We compared farmed Atlantic cod Gadus morhua morphology to that of wild cod from the same ancestral population. Traditional and geometric morphometrics showed that farmed cod had relatively smaller fins, heads, eyes, and jaws than wild cod for a given size. Conversely, drumming muscle size and metrics of body and liver condition were greater in farmed fish. As the observed differences are likely due to phenotypic plasticity, their fitness consequences for escaped farmed fish may be transient. ...
Phosphodiesterases (PDEs) are enzymes that play a major role in cell signalling by hydrolysing the secondary messengers cyclic adenosine monophosphate (cAMP) and/or cyclic guanosine monophosphate (cGMP) throughout the body and brain. Altered cyclic nucleotide-mediated signalling has been associated with a wide array of disorders, including neurodegenerative disorders. Recently, PDE5 has been shown to be involved in neurodegenerative disorders such as Alzheimers disease, but its precise role has not been elucidated yet. To visualize and quantify the expression of this enzyme in brain, we developed a radiotracer for specific PET imaging of PDE5. A quinoline-based lead compound has been structurally modified resulting in the fluoroethoxymethyl derivative ICF24027 with high inhibitory activity towards PDE5 (IC50 = 1.86 nM). Radiolabelling with fluorine-18 was performed by a one-step nucleophilic substitution reaction using a tosylate precursor (RCY(EOB) = 12.9% ± 1.8%; RCP > 99%; SA(EOS) = 70-126 GBq
wherein Mn is manganese. L or each L independently is a polydentate ligand, preferably a cyclic or acyclic compound containing 3 nitrogen atoms. Each X is independently a coordinating species and each μ-X is independently a bridging coordinating species, selected from the group consisting of: RO-, Cl-, Br-, I--, F-, NCS-, N3--, I3-, NH3, NR3, RCOO-, RSO3-, RSO4-, OH-, O2-, O22-, HOO-, H2O, SH-, CN-, OCN-, and S42- and combinations thereof, wherein R is a C1-C20 radical selected from the group consisting of alkyl, cycloalkyl, aryl, benzyl and combinations thereof. Y is a non-coordinating counter ion. The non-coordinating counter ion Y may provide for the charge neutrality of the complex and the value of n depends upon the charge of the cationic complex and anionic counter ion Y, for example, n may be 1 or 2. Counter ion Y may for instance be an anion selected from the group consisting of RO-, Cl-, Br-, I-, F-, SO42-, RCOO-, PF6-, tosylate, triflate (CF3SO3-) and a combination thereof with R once ...
Supplementary MaterialsS1 Dataset: PSFS Validation for snakebite data. assessed using concurrent validity correlating with the other assessments. The MCID was evaluated using the following criteria: (1) the distribution of stable patients according to both standard error of measurement (SEM) and responsiveness methods, and (2) anchor-based solutions to evaluate between individuals also to identify discriminant ability of the positive change using a recipient operator quality (ROC) curve and optimum cutoff point. Outcomes A complete of 86 sufferers were evaluated within this scholarly research. The common PSFS scores had HAS3 been 5.37 (SD 3.23), 7.95 (SD 2.22), and 9.12 (SD 1.37) in 3, 7, and 10 times, respectively. Negligible flooring effect was noticed (optimum of 8% at 3 times); nevertheless, a ceiling impact was noticed at 17 times (25%). The LY-2584702 tosylate salt PSFS demonstrated good dependability with an interior persistence of 0.91 (Cronbachs alpha) (95% CI 0.88, 0.95) and a temporal ...
Regulation of gene expression plays a central role in embryonic development. Early stages are controlled by gametic transcripts, which are subsequently substituted with transcripts from the genome of the zygote. Transcriptomic analyses provide an efficient approach to explore the temporal gene expression profiles in embryos and to search for the developmental regulators. We report a study of early Atlantic cod development that used a genome-wide oligonucleotide microarray to examine the composition and putative roles of polyadenylated transcripts. The analyses were carried out in unfertilized oocytes, newly fertilized oocytes and embryos at the stages of mid-blastula transition and segmentation. Numerous genes transcribed in oocytes are involved in multiple aspects of cell maintenance and protection, including metabolism, signal perception and transduction, RNA processing, cell cycle, defense against pathogens and DNA damage. Transcripts found in unfertilized oocytes also encoded a large number of
Dermira, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil. Cimzia is an injectable biologic tumor necrosis factor-alpha inhibitor, or TNF inhibitor that is approved and marketed for the treatment of numerous inflammatory diseases spanning multiple medical specialties, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohns disease, in multiple countries, including the United States. Glycopyrronium tosylate is a small molecule anticholinergic product for topical application for the treatment of primary axillary hyperhidrosis. Olumacostat glasaretil is a small molecule that targets sebum production following topical application for the treatment of acne.
Harvesting may be a potent driver of demographic change and contemporary evolution, which both may have great impacts on animal populations. Research has focused on changes in phenotypic traits that are easily quantifiable and for which time series exist, such as size, age, sex, or gonad size, whereas potential changes in behavioural traits have been under-studied. Here, we analyse potential drivers of long-term changes in a behavioural trait for the Northeast Arctic stock of Atlantic cod Gadus morhua, namely choice of spawning location. For 104 years (1866-1969), commercial catches were recorded annually and reported by county along the Norwegian coast. During this time period, spawning ground distribution has fluctuated with a trend towards more northerly spawning. Spawning location is analysed against a suite of explanatory factors including climate, fishing pressure, density dependence, and demography. We find that demography (age or age at maturation) had the highest explanatory power for ...
The aim of this study was to compare the nutritional composition and effects of short periods with cultivated copepod nauplii versus rotifers in first-feeding. Atlantic cod (Gadus morhua) and ballan wrasse (Labrus bergylta) larvae were given four different dietary regimes in the earliest start-feedi.... ...
The aim of this study was to compare the nutritional composition and effects of short periods with cultivated copepod nauplii versus rotifers in first-feeding. Atlantic cod (Gadus morhua) and ballan wrasse (Labrus bergylta) larvae were given four different dietary regimes in the earliest start-feedi.... ...
Jarrow Formulas SAMe 400 provides a full 400 mg SAMe (net yield) from 800 mg of SAMe tosylate disulfate. SAMe 400 is manufactured under low temperature and low humidity and is enteric-coated to ensure a biologically active product. Contains More of the Active S,S Form Found in all living cells, SAMe is a metabolite of methionine (an essential amino acid). SAMe is a chiral molecule consisting of two forms: (S,S) SAMe and (R,S) SAMe. The biologically active form is the (S,S) structure, while the (R,S) structure is biologically inactive.Jarrow Formulas SAMe is made naturally by microbiological fermentation and then specially processed without chemical solvents to preserve 68-80% (S,S) SAMe, the highest active level available. SAMe has been clinically shown to have the following benefits: Joint Strength SAMe supports the production of healthy connective tissue through transulfuration.* In this process, critical components of connective tissue, known as glycosaminoglycans (GAGs), including glucosamine
2. A medical implant according to claim 1, characterized in that the nitrostatin is a compound of general formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof ##STR00006## Wherein: R is ##STR00007## B1 and B2 are: a) a further NO-releasing group comprising one or more of --NO2, --ONO2, or cinidomine (II), b) a tosylate or mesylate group, c) a straight-chain or branched C1 to C20 alkyl, optionally substituted with one or more substituents selected from the group comprising the following: halogen atoms, hydroxy, --ONO, d) a heterocyclic saturated, unsaturated, or aromatic ring containing at least one heteroatom selected from nitrogen, oxygen, sulfur, and halogen atoms; the ring being additionally substituted with side chains having a straight-chain or branched alkyl containing 1 to 10 carbon atoms, e) a cycloalkylene or cycloarylene ring containing 5 to 7 carbon atoms, the ring being substituted with side chains having a straight-chain or branched alkyl containing 1 to 10 ...
Close The Infona portal uses cookies, i.e. strings of text saved by a browser on the users device. The portal can access those files and use them to remember the users data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser. ...
branch and an active vasodilator branch [11]. Nonthermoregulatory reflexes, which include skin blood flow responses to changes in arterial and central venous pressure and exercise stresses, also operate through the two aforementioned branches of the sympathetic nervous system; however, the glabrous/ palmar skin operates only through the vasoconstrictor branch [10,11,41]. In the auto-regulation process, throughout a specific range of arterial blood pressure, steady-state blood flow is maintained at a fairly constant level [44]. Previous reports on cutaneous circulation has shown that, independent of neural control of blood flow, glabrous/palmar skin has the ability to buffer blood pressure oscillations and demonstrates a degree of dynamic auto-regulation. Conversely, nonglabrous or hairy skin has a diminished dynamic auto regulatory capacity [42]. We first tried to relate observations in the present study to some of the physiological findings reported earlier on the cutaneous responses to ...
Impact of overactive bladder on work productivity Coyne KS, Sexton CC, Thompson CL, Clemens JQ, Chen CI, Bavendam T, Dmochowski R 80: 97-107, 2012 This was a large population-based, cross-sectional. ...
... bretylium compounds MeSH D02.092.877.096.333.150 - bretylium tosylate MeSH D02.092.877.233 - betalains MeSH D02.092.877.233.500 ... bretylium compounds MeSH D02.675.276.175.150 - bretylium tosylate MeSH D02.675.276.190 - cetrimonium compounds MeSH D02.675. ...
... (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In ... On June 8, 2011 bretylium tosylate was announced as unavailable in the US after request of Hospira Inc. to withdraw its NDA ... Quaternization of o-bromo-N,N-dimethylbenzylamine with ethyl-p-toluenesulfonate yields bretylium p-toluenesulfonate (tosylate ... US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate ...
What is bretylium tosylate? Meaning of bretylium tosylate medical term. What does bretylium tosylate mean? ... Looking for online definition of bretylium tosylate in the Medical Dictionary? bretylium tosylate explanation free. ... bretylium tosylate. bretylium tosylate. [britil′ē·əm] an antiarrhythmic agent. indication It is prescribed in the treatment of ... Bretylium tosylate , definition of bretylium tosylate by Medical dictionary https://medical-dictionary.thefreedictionary.com/ ...
Prevention of Recurrent Ventricular Tachycardia with Oral Bretylium Tosylate REX N. MACALPIN, M.D.; EDWIN G. ZALIS, M.D.; ... The initiation of therapy with bretylium tosylate abruptly terminated the recurrences of arrhythmia, and the patient has had no ... Prevention of Recurrent Ventricular Tachycardia with Oral Bretylium Tosylate. Ann Intern Med. 1970;72:909-912. doi: https://doi ...
BRETYLIUM TOSYLATE IN DEXTROSE 5%. bretylium tosylate. INJECTABLE;INJECTION. 019005-002. Apr 29, 1986. DISCN. No. No. ➠ Sign Up ... BRETYLIUM TOSYLATE IN DEXTROSE 5%. bretylium tosylate. INJECTABLE;INJECTION. 019005-003. Apr 29, 1986. DISCN. No. No. ➠ Sign Up ... BRETYLIUM TOSYLATE IN DEXTROSE 5%. bretylium tosylate. INJECTABLE;INJECTION. 019005-001. Apr 29, 1986. DISCN. No. No. ➠ Sign Up ... BRETYLIUM TOSYLATE IN DEXTROSE 5% Drug Profile. « Back to Dashboard. When do Bretylium Tosylate In Dextrose 5% patents expire, ...
N-Ethyl-N-(o-bromobenzyl)-N,N-dimethylammonium tosylate. *Benzenemethanaminium, 2-bromo-N-ethyl-N,N-dimethyl-, salt with 4- ...
Bretylium tosylate may aggravate digitalis toxicity. In digitalized patients, bretylium tosylate should be used only if the ... Following injection of Bretylium Tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, ... Use of Bretylium Tosylate Injection, USP should be limited to intensive care units, coronary care units or other facilities ... Bretylium Tosylate Injection, USP should be diluted prior to intravenous use, but may be given undiluted for immediately life- ...
New Drugs: Bretylium Tosylate: A Newly Available Antiarrhythmic Drug for Ventricular Arrhythmias ROBERT H. HEISSENBUTTEL, M.D ... Bretylium tosylate (Bretylol) has recently been approved for parenteral use against resistant ventricular arrhythmias. The ... New Drugs: Bretylium Tosylate: A Newly Available Antiarrhythmic Drug for Ventricular Arrhythmias. Ann Intern Med. 1979;91:229- ... Bretylium is an adrenergic neuronal blocking agent taken up selectively at peripheral adrenergic nerve terminals, where it ...
Remifentanil Hydrochloride reference guide for safe and effective use from the American Society of Health-System Pharmacists (AHFS DI).
Bretylium Tosylate Injection. What is this drug used for?. *It is used to treat certain types of abnormal heartbeats. ...
Comparing the effectiveness of methoxamine and bretylium tosylate on electrically-induced ventricular fibrillation in dogs ... Post a Comment for Comparing the effectiveness of methoxamine and bretylium tosylate on electrically-induced ventricular ... Add tags for Comparing the effectiveness of methoxamine and bretylium tosylate on electrically-induced ventricular fibrillation ... Comparing the effectiveness of methoxamine and bretylium tosylate on electrically-induced ventricular fibrillation in dogs. ...
bretylium tosylate. Medical browser ? *▲. *adrenaline junkie. *adrenaline receptors. *adrenaline television. *adrenalinemia. * ...
Bretylium tosylate: http://www.medicinenet.com/bretylium_tosylate-injection/article.htm; [online] retrieved from the internet ... Krieglstein, "The influence of bretylium tosylate on the intraocular pressure of the rabbit" Graefes Archiv. Ophthalmologie 197 ... wherein the compound is selected from the group consisting of bretylium and methylapogalanthamine. ... bretylium, reserpine, phenoxybenzamine, or guanethidine, will relieve SMP using the method according to the present invention. ...
Bretylium. Bretylium Tosylate. Calcitriol. Calcitriol. Calcium Folinat Bigmar. Folic Acid (Calcium Folinate). ...
Amiodarone • Bretylium tosylate • Bunaftine • Dofetilide • Ibutilide • Sotalol. class IV. Verapamil • Diltiazem. see Calcium ...
386786 - Bretylium tosylate: a review.. Publication Detail: Type: Journal Article; Review Journal Detail: Title: Molecular ...
Bretylium Tosylate (Bretylol) • Class; antiadysrhythmic • Different from all other antidysrhythmics • Does not suppress ... administer bretylium drip at 1-2 mg/min. • How supplied • 50 mg/ml in 10 ml preload ...
Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In ... On June 8, 2011 bretylium tosylate was announced as unavailable in the US after request of Hospira Inc. to withdraw its NDA ... Quaternization of o-bromo-N,N-dimethylbenzylamine with ethyl-p-toluenesulfonate yields bretylium p-toluenesulfonate (tosylate ... US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate ...
Bretylium Tosylate In Dextrose 5% In Plastic Container - injectable, injection (400mg/100ml) - Bretylium Tosylate (Bretylium ...
Bretylium Tosylate - injectable, injection (50mg/ml) - Bretylium Tosylate (Bretylium Tosilate) * Caffeine Citrate - solution, ...
380436 - Bretylium tosylate: a newly available antiarrhythmic drug for ventricular arrhythmias.. 25351576 - Microrna induced ...
Bretylium tosylatePDL. I. DEC / 13. Brexpiprazole or its saltsPDL. I. APR / 17. ...
Drugs. The following drugs were used: bretylium tosylate (Burroughs Wellcome, Research Triangle Park, NC); (-)-cocaine ... Effect of Reboxetine and Cocaine on the Inhibitory Action of Bretylium. Bretylium (10-6 M) blocked the stimulation-evoked ... bretylium, 10-6 M; ○, untreated. The arrow indicates addition of bretylium (10-6 M). A, ▴, pretreated with reboxetine (10-7 M ... Reboxetine (10-7 M) and cocaine (10-5 M) prevented the inhibitory action of bretylium (10-6 M). Reboxetine (10-8-10-5 M), ...
Nowak RM, Bodnar TJ, Dronen S. Bretylium tosylate as initial treatment for cardiopulmonary arrest: randomized comparison with ...
Goldberger A L et al., "Vagally-mediated atrial fibrillation in dogs: conversion with bretylium tosylate," Int J Cardiol 13 (1 ...
ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias PR Newswire. ... ANI Pharmaceuticals Announces Launch of Bretylium Tosylate Injection, USP 50 mg/mL PR Newswire. ...
... bretylium tosylate, quinidine sulfate and quinidine gluconate; drugs used in the treatment of hypertension such as propranolol ...
... bretylium tosylate, quinidine sulfate and quinidine gluconate; therapeutic agents used in the treatment of hypertension such as ...
Bretylium Tosylate. Brexpiprazole. Brimonidine. Brimonidine Tartrate. Brinzolamide. Brivaracetam. Bromazepam. Bromfenac ...
ANI Announces Plans to Launch Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml) for Ventricular Arrhythmias ...
However, bretylium tosylate could not suppress increase of systemic blood pressure and heart rate in response to carotid ... For example, Goodchild and Serrao [6] used bretylium tosylate and propranolol in combination with bilateral vagotomy and ... Ledsome JR, Linden RJ: The effect of bretylium tosylate on some cardiovascular reflexes. J Physiol (Lond) 1964; 170:442-55 ... indicating that efferent sympathetic activity was increased after bretylium tosylate. Therefore, it is unlikely that ...
Bretylium tosylate did not increase GTP hydrolysis in HL-60 membranes or with Gi/G(o) proteins. Our data suggest that ... The class III antiarrhythmic drugs amiodarone and bretylium tosylate are cationic/amphiphilic, and various substances with ... amiodarone but not bretylium tosylate is a direct activator of Gi and G(o) proteins and that amiodarone activates nonselective ...
  • Bretylium Tosylate Injection, USP is indicated in the prophylaxis and therapy of ventricular fibrillation. (bretylium.com)
  • Bretylium Tosylate Injection, USP is also indicated in the treatment of life-threatening ventricular arrhythmias, such as ventricular tachycardia that have failed to respond to adequate doses of a first-line antiarrhythmic agent, such as lidocaine. (bretylium.com)
  • Use of Bretylium Tosylate Injection, USP should be limited to intensive care units, coronary care units or other facilities where equipment and personnel for constant monitoring of cardiac arrhythmias and blood pressure are available. (bretylium.com)
  • Following injection of Bretylium Tosylate there may be a delay of 20 minutes to 2 hours in the onset of antiarrhythmic action, although it appears to act within minutes in ventricular fibrillation. (bretylium.com)
  • Bretylium Tosylate Injection, USP should be diluted prior to intravenous use, but may be given undiluted for immediately life-threatening ventricular arrythmias. (bretylium.com)
  • This Important Safety Information does not include all the information needed to use Bretylium Tosylate Injection, USP safely and effectively. (bretylium.com)
  • See full Prescribing Information for Bretylium Tosylate Injection, USP. (bretylium.com)
  • BAUDETTE, Minn., Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml). (insidertracking.com)
  • Bretylium (also bretylium tosylate) is an antiarrhythmic agent. (wikipedia.org)
  • Bretylium tosylate (Bretylol) has recently been approved for parenteral use against resistant ventricular arrhythmias. (annals.org)
  • Bretylium tosylate should be avoided in patients with fixed cardiac output since severe hypotension may result. (bretylium.com)
  • Bretylium should be used only in an ICU or emergency department setting and should not be used elsewhere due to its dramatic actions and its predominant side effect of hypotension. (wikipedia.org)
  • Bretylium is an adrenergic neuronal blocking agent taken up selectively at peripheral adrenergic nerve terminals, where it initially releases norepinephrine (sympathomimetic effect) and then produces adrenergic neuronal blockade. (annals.org)
  • US 3441649, Marvin B Bacaner, "Suppression of cardiac ventricular fibrillation and cardiac arrhythmias with bretylium tosylate", assigned to University of Minnesota Khan, M. Gabriel (December 14, 2005). (wikipedia.org)
  • Should we bring Bretylium back in cardiac arrest? (resus.com.au)
  • Experiments were performed before and after intravenous bretylium tosylate (10 mg/kg), a compound which prevents the outflow of catecholamines from the sympathetic postganglionic neurons. (elsevier.com)
  • EFS-dependent contractions had ABT-888 been virtually abolished from the sympathetic nerve obstructing agent bretylium tosylate (3 10?5 M) and by the alpha-adrenergic antagonist terazosin (10?6 M), confirming these responses are neuronal in origin and adrenergic in character (data not demonstrated). (conferencedequebec.org)
  • Bretylium tosylate may aggravate digitalis toxicity. (bretylium.com)
  • In digitalized patients, bretylium tosylate should be used only if the etiology of the arrhythmia does not appear to be digitalis toxicity and other antiarrhythmic drugs are not effective. (bretylium.com)
  • The class III antiarrhythmic drugs amiodarone and bretylium tosylate are cationic/amphiphilic, and various substances with these physico-chemical properties are known to directly activate heterotrimeric regulatory G proteins. (aspetjournals.org)
  • Our data suggest that amiodarone but not bretylium tosylate is a direct activator of Gi and G(o) proteins and that amiodarone activates nonselective cation channels in HL-60 cells via Gi proteins and independently of Ca2+ mobilization from intracellular stores. (aspetjournals.org)
  • There are no contraindications to use bretylium tosylate in treatment of ventricular fibrillation or life-threatening refractory ventricular arrhythmias, except in the case of digitalis induced arrhythmias. (bretylium.com)
  • Bretylium also has a unique action in that it may cause chemical cardioversion of ventricular fibrillation or facilitate cardioversion of ventricular fibrillation refractory to d.c. cardioversion. (alpfmedical.info)
  • We report the findings in a patient in whom bretylium was the only agent that suppressed refractory VT and ventricular fibrillation. (levelofhealth.com)
  • Clinical studies have shown parenteral bretylium to be effective in suppressing ventricular arrhythmias, particularly recurrent, drug resistant ventricular tachycardia or ventricular fibrillation. (annals.org)
  • Comparing the effectiveness of methoxamine and bretylium tosylate on electrically-induced. (musc.edu)
  • when methoxamine was used than when no drug therapy or bretylium were used . (musc.edu)
  • Bretylium increases ventricular fibrillation threshold and prevents the decrease in ventricular fibrillation threshold associated with myocardial ischemia. (annals.org)
  • The initiation of therapy with bretylium tosylate abruptly terminated the recurrences of arrhythmia, and the patient has had no episodes for 20 months while taking 400 mg, by mouth, every 8 hr. (annals.org)
  • Avoid simultaneous initiation of therapy with digitalis glycosides and bretylium tosylate. (bretylium.com)
  • Bretylium Tosylate In Dextrose 5% is a drug marketed by Abbott , B Braun , Baxter Hlthcare , and Hospira Inc . and is included in four NDAs. (drugpatentwatch.com)
  • Bretylium will remain on the FDA's discontinued drug list since its withdrawal was not the result of a safety or effectiveness concern. (wikipedia.org)
  • The change in flow was studied after (a) injections of atropine and propranolol (a beta adrenergic blocking drug), (b) injections of phenoxybenzamine (an alpha blocking drug) and (c) bretylium tosylate (an adrenergic neurone blocking drug). (gla.ac.uk)
  • Bretylium tosylate is a class 3 antiarrhythmie drug useful in the treatment of drug-resistant ventricular tachycardia (VT) and ventricular and fibrillation. (levelofhealth.com)
  • When do Bretylium Tosylate In Dextrose 5% patents expire, and when can generic versions of Bretylium Tosylate In Dextrose 5% launch? (drugpatentwatch.com)
  • The pharmacologic action of bretylium is complex, and its antiarrhythmic action differs significantly from other drugs. (annals.org)
  • 11. The method of claim 1 wherein the compound is bretylium. (google.com)
  • By the release of the AHA 2005 ECC/ACC guidelines there is no mention of Bretylium and it is virtually unavailable throughout most of the world. (wikipedia.org)
  • Following a brief presentation at EMCore Hong Kong in April of this year, that challenged our thinking, I have asked our expert colleague, Dr Will Davies, to expand on an argument he put forward, (in our clinical topics series), that we should revisit the use of bretylium tosylate in cardiopulmonary resuscitation, especially in the treatment of. (resus.com.au)
  • The browser window or tab for bretylium.com will remain open. (bretylium.com)
  • ANI Pharmaceuticals is not responsible for the privacy policy, the content, or the accuracy of any websites accessed through a link on the bretylium.com site. (bretylium.com)
  • Reboxetine (10 - 7 M) and cocaine (10 - 5 M) prevented the inhibitory action of bretylium (10 - 6 M). Reboxetine (10 - 8 -10 - 5 M), desipramine (10 - 7 -10 - 4 M), and cocaine (10 - 6 -10 - 5 M) increased the stimulation-evoked [ 3 H]norepinephrine release. (aspetjournals.org)
  • Bretylium tosylate has a unique mode of action. (alpfmedical.info)
  • To return to bretylium.com at any time, close this tab or window. (bretylium.com)
  • Furthermore, the dECM gels didn't create any deleterious influence on the cells or hindered their migration because the high cell viability ( 90%) was taken care of when the test was analyzed Bretylium tosylate on day time 7 and 14 with energetic cell proliferation (Fig. 5e). (thebiotechdictionary.com)
  • All pets housed under particular pathogen-free conditions within an Bretylium tosylate authorized animal service at Pohang College or university of Technology and Technology (POSTECH) Biotech Middle. (rectalcancersite.com)
  • The American Heart Association removed bretylium from their 2000 ECC/ACC guidelines due to its unproven efficacy and ongoing supply problems. (wikipedia.org)
  • Many have cited these supply problems as an issue of raw materials needed in the production of Bretylium. (wikipedia.org)
  • This Bretylium tosylate restriction decreases the decision of materials due to the necessity to use within an aqueous or aqueous gel environment11,12. (thebiotechdictionary.com)
  • Recently however , bretylium has also been recommended as therapy during resuscitation from ventricular fibrillation . (musc.edu)
  • Keep patients supine until tolerance to the hypotensive effect of bretylium tosylate develops. (bretylium.com)